Previous close | 51.71 |
Open | 52.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 52.10 - 53.88 |
52-week range | 50.81 - 75.42 |
Volume | |
Avg. volume | 2,831 |
Market cap | 113.961M |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 0.12 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WILMINGTON, Del., April 30, 2024--Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del. & SAN DIEGO, April 23, 2024--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del., April 11, 2024--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024.